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ically requested, were included in 18 dossiers, and off-
label information was included in 7. Of the 50 products
submitted, 24 (48%) were added to Formulary. CON-
CLUSIONS: Compliance with the guidelines has im-
proved over the past 30 months. Overall, a majority of
the submissions included complete clinical information
and some type of economic analysis. There remains,
however, significant opportunity for improvement, par-
ticularly in the presentation of economic evaluation data
and the dissemination of unpublished studies.
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Obesity is now recognized as a chronic health condition
instead of a cosmetic or lifestyle issue. Orlistat and
sibutramine are effective weight-loss/weight-maintenance
agents. Insurers argue that the high prevalence of obesity
(i.e., body mass index (BMI)3 30kg/m2), questionable
long-term health benefits, and cost of these drugs make it
unfeasible to cover them. Proponents claim decreases in
obesity’s comorbidities would offset acquisition costs.
OBJECTIVES: To provide evidence for a rational reim-
bursement policy for pharmacological treatments of obe-
sity in adults. METHODS: A Markov decision analytic
model was used to evaluate the cost-effectiveness of orlistat
(120mg TID) and sibutramine (5–20mg QD) relative to
diet and exercise alone. The model analyzed a hypothetical
population of obese, but otherwise healthy 30 year olds
over their lifetime. Estimates of efficacy and tolerance were
derived from a meta-analysis of randomized, placebo-con-
trolled trials of orlistat and sibutramine. The Framingham
Study was used to derive risk-adjusted equations for the in-
cidence of hypertension, dyslipidemia, and DM as well as
the incidence of CV events, CV-attributable death, and
non-CV death. Equations were adjusted for known risk
factors, including BMI. The reference case analysis used the
societal perspective and included both direct and indirect
costs (discount rate, 3%). Costs were derived from the liter-
ature and inflated to year 2000 Canadian dollars (CDN$).
Utilities were derived from a Canadian health survey and
from the literature. Decision index: incremental cost per
quality adjusted life year ($/QALY). A Monte Carlo simu-
lation will be used to perform a sensitivity analyses around:
estimated weight-loss, estimated dropout rates, estimated
weight regain, cost of treatment, and major clinical events.
RESULTS: Results for the base case (i.e., societal view-
point) and third party payer (i.e., Ministry of Health) per-
spectives will be presented and discussed. Emphasis will be
placed on the decision model approach for informing for-
mulary decisions on “lifestyle” drugs.
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Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. In a recent re-
port (JCO, 2000;18:3302), data from 40 published cost-
utility studies were presented in a league table format.
Most of those studies utilized nurses or physicians as
proxies for the pt. in determining utility. OBJECTIVE:
To determine if there is a difference between utility scores
obtained from metastatic breast cancer pt. and oncology
nurses. METHODS: Using eight modified Markov mod-
eled health states (Pharmacoeconomics, 1996; 60:504)
describing metastatic breast cancer; the standard gamble
procedure was utilized to obtain utility scores from 45
patients and 57 oncology nurses. Utility values were mea-
sured on a scale between 0.0 and 1.0. Independent t-tests
were used to test for differences between groups using an
alpha level of 0.05 (2-sided). RESULTS: Significant dif-
ferences were found on all eight modeled health states:
CONCLUSION: These results show that patients have a
higher utility for health than perceived by nurses. These
data leads to the question of whose utility values should
be used for cost-utility analysis in oncology.
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Modeled Disease State
Mean Utility
Score (SD)
Patients/Nurses
(n  45; n  57)
P
Value
95%
Confidence
Intervals
Partial Response (PR) .84 (.11)/.71 (.22) .0001 .06–.20
PR with Severe
Peripheral Edema .78 (.17)/.63 (.24) .0001 .08–.24
PR with Severe
Peripheral Neuropathy .76 (.13)/.56 (.24) .0001 .12–.28
Before Second Line
Treatment Begins .73 (.16)/.59 (.22) .0001 .06–.22
Stable Disease .72 (.15)/.54 (.22) .0001 .11–.26
Late Progressive Disease .63 (.18)/.45 (.25) .0001 .10–.27
Terminal Disease .40 (.26)/.19 (.21) .0001 .13–.31
Sepsis .39 (.25)/.20 (.23) .0001 .09–.28
